appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Gland Pharma Ltd
GLAND
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 7.52%
Recent NewsAll news
U.S. FDA issues two observations for Gland Pharma facility
1 day ago•The Hindu
Gland Pharma’s Hyderabad Facility Gets Two US FDA Observations
1 day ago•Bloomberg Quint
USFDA conducts surprise inspection of Gland Pharma’s Dundigal facility
1 day ago•Business Standard
Recent EventsAll events
Press Release
Gland Pharma Limited has informed the Exchange regarding a press release dated July 23, 2024, titled "Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution ". | Download
Gland Pharma Limited has informed the Exchange regarding a press release dated July 23, 2024, titled "Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution ". | Download
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 6.03%